These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20595094)

  • 1. TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study.
    Mallo M; Osca G; Solórzano J; Arenillas L; Florensa L; Solé F
    Haematologica; 2010 Oct; 95(10):1798-800. PubMed ID: 20595094
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
    Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
    Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
    Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
    Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
    Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.
    Grossmann V; Kohlmann A; Eder C; Haferlach C; Kern W; Cross NC; Haferlach T; Schnittger S
    Leukemia; 2011 May; 25(5):877-9. PubMed ID: 21339759
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms.
    Lin HC; Hwang DY; Lim KH
    Med Oncol; 2016 Aug; 33(8):92. PubMed ID: 27418193
    [No Abstract]   [Full Text] [Related]  

  • 7. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
    Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
    Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
    Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
    Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial myeloid malignancies with germline TET2 mutation.
    Duployez N; Goursaud L; Fenwarth L; Bories C; Marceau-Renaut A; Boyer T; Fournier E; Nibourel O; Roche-Lestienne C; Huet G; Beauvais D; Berthon C; Cambier N; Quesnel B; Preudhomme C
    Leukemia; 2020 May; 34(5):1450-1453. PubMed ID: 31827242
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of myelodysplastic/myeloproliferative neoplasms.
    Reiter A; Invernizzi R; Cross NC; Cazzola M
    Haematologica; 2009 Dec; 94(12):1634-8. PubMed ID: 19996113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AML1/RUNX1 fusion gene and t(5;21)(q13;q22) in a case of chronic myelomonocytic leukemia with progressive thrombocytopenia and monocytosis.
    Liu S; Li C; Bo L; Dai Y; Xiao Z; Wang J
    Cancer Genet Cytogenet; 2004 Jul; 152(2):172-4. PubMed ID: 15262442
    [No Abstract]   [Full Text] [Related]  

  • 14. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
    Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
    J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased TET2 gene expression during chronic myeloid leukemia progression.
    Albano F; Anelli L; Zagaria A; Coccaro N; Minervini A; Rossi AR; Specchia G
    Leuk Res; 2011 Nov; 35(11):e220-2. PubMed ID: 21794915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
    Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
    Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tet2 restrains inflammatory gene expression in macrophages.
    Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
    Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.
    Palomo L; Malinverni R; Cabezón M; Xicoy B; Arnan M; Coll R; Pomares H; García O; Fuster-Tormo F; Grau J; Feliu E; Solé F; Buschbeck M; Zamora L
    Epigenetics; 2018; 13(1):8-18. PubMed ID: 29160764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.
    Kohlmann A; Klein HU; Weissmann S; Bresolin S; Chaplin T; Cuppens H; Haschke-Becher E; Garicochea B; Grossmann V; Hanczaruk B; Hebestreit K; Gabriel C; Iacobucci I; Jansen JH; te Kronnie G; van de Locht L; Martinelli G; McGowan K; Schweiger MR; Timmermann B; Vandenberghe P; Young BD; Dugas M; Haferlach T
    Leukemia; 2011 Dec; 25(12):1840-8. PubMed ID: 21681191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.